Why THRβ Is the Liver’s Most Tractable Metabolic Target

Thyroid hormone receptor beta (THRβ) is the dominant isoform expressed in the liver, making it a highly selective pharmacological lever for correcting the hepatic lipid dysregulation that underlies metabolic dysfunction-associated steatohepatitis (MASH). Unlike systemic thyroid hormone supplementation — which risks cardiac and bone side effects via THRα — selective THRβ agonists concentrate their activity in hepatocytes, where they upregulate fatty acid oxidation, reduce lipid synthesis, and can attenuate the inflammatory and fibrotic cascades that define MASH pathology.

MASH — previously classified as non-alcoholic steatohepatitis (NASH) — sits at the intersection of the global obesity epidemic and metabolic syndrome. It is characterised by hepatic steatosis, lobular inflammation, and progressive fibrosis that can advance to cirrhosis and hepatocellular carcinoma. According to data published by WHO, metabolic liver disease represents one of the fastest-growing causes of liver-related morbidity worldwide, driving intense pharmaceutical investment in novel pharmacological targets.

THRβ’s liver-selective expression profile makes it an attractive target precisely because it allows researchers to harness the lipid-lowering and metabolic benefits of thyroid hormone signalling without the systemic toxicities that made earlier non-selective thyroid hormone analogues clinically impractical. The validation of this mechanism by the FDA’s first-ever MASH drug approval — resmetirom — has intensified scrutiny of every next-in-class THRβ candidate in development.

Terns Pharmaceuticals’ Patent Portfolio: Scope and Strategy

Terns Pharmaceuticals has filed more than 30 US patent applications covering selective THRβ agonist compounds for treating metabolic diseases including NAFLD and NASH/MASH, with publications spanning 2021 through 2024 — representing one of the most concentrated single-assignee patent campaigns in the MASH THRβ space. The breadth of this portfolio, encompassing multiple distinct chemical scaffolds across numerous patent families, signals a deliberate strategy to establish layered IP protection around TERN-501 and related compounds.

The earliest publications in the Terns portfolio date to August 2021, with three simultaneous patent application publications (US20210261527A1, US20210261528A1, US20210261529A1, US20210261530A1, US20210261531A1, US20210261532A1) covering distinct chemical scaffolds. This simultaneous multi-family filing approach is characteristic of companies seeking to establish broad compositional coverage around a lead compound while protecting backup series — a standard tactic in pharmaceutical IP strategy reviewed by practitioners at organisations such as EPO.

The portfolio includes at least one granted patent: US11214563B2, granted January 4, 2022, which claims specific chemical structures of selective THRβ agonist compounds for treating NAFLD and NASH. The remaining applications, spanning publications through January 2024, represent a combination of continuation applications, divisional filings, and new compound families — each designed to extend the protective perimeter around the core TERN-501 chemical space.

Chemical Scaffold Diversity as an IP Moat

A notable feature of the Terns portfolio is the filing of multiple patent families covering structurally distinct chemical scaffolds for THRβ agonism. Rather than relying on a single composition-of-matter patent, Terns has pursued parallel patent families that cover different molecular architectures all capable of selectively activating THRβ. This approach creates a layered IP moat: even if one chemical series is designed around by a competitor, the remaining families continue to provide exclusivity over a broad swath of the THRβ agonist chemical space relevant to MASH treatment.

The Competitive Landscape: TERN-501 vs. Resmetirom and the MASH Field

TERN-501 enters a MASH therapeutic landscape that has been fundamentally reshaped by the FDA approval of resmetirom (Rezdiffra), making it the first approved pharmacological treatment for MASH with liver fibrosis. Resmetirom, developed by Madrigal Pharmaceuticals, is itself a selective THRβ agonist — meaning TERN-501 and resmetirom share the same primary mechanism of action while differing in their chemical structures and, potentially, their pharmacokinetic and pharmacodynamic profiles.

“Terns Pharmaceuticals has filed more than 30 US patent applications covering selective THRβ agonist compounds for treating NAFLD and NASH/MASH — one of the most concentrated single-assignee patent campaigns in the MASH THRβ space.”

The competitive significance of TERN-501 lies partly in its structural differentiation from resmetirom. Because Terns Pharmaceuticals has filed patent families covering multiple distinct chemical scaffolds — each independently claiming selective THRβ agonism for NAFLD/NASH treatment — TERN-501’s composition-of-matter protection is unlikely to be threatened by resmetirom’s existing patents. This is a key consideration for licensing, partnership, and acquisition discussions in the MASH field, which FDA has identified as a priority therapeutic area.

Beyond resmetirom, the MASH drug development field includes candidates targeting complementary pathways — including FXR agonists, GLP-1 receptor agonists, and ACC inhibitors — many of which are being explored in combination with THRβ agonists. The combination potential of THRβ agonists with GLP-1 receptor agonists has attracted particular attention given the overlapping metabolic benefits of both mechanisms, as discussed in research published by NEJM.

Reading the IP Signals: What Patent Filings Reveal About Clinical Ambition

Patent filing patterns are among the most reliable leading indicators of a company’s clinical and commercial ambitions — and the Terns Pharmaceuticals THRβ portfolio sends clear signals on multiple dimensions. The sustained pace of new publications from 2021 through 2024, encompassing both original filings and continuation applications, indicates active prosecution of a portfolio designed to track and protect a compound moving through clinical development.

Several structural features of the portfolio are worth noting for IP professionals and R&D leaders evaluating this space:

• Multi-family filing strategy: Terns has filed numerous patent families, each covering distinct chemical scaffolds for selective THRβ agonism. This approach maximises the geographic and chemical scope of IP protection and reduces the risk of a single invalidation event undermining the entire portfolio.
• Continuation filing activity: The presence of continuation applications in the 2022–2024 period suggests active prosecution strategy, with claims being refined in response to USPTO examination and potentially broadened or narrowed to optimise protection around the clinical compound.
• Dual protection model: The portfolio covers both composition-of-matter claims (the chemical compounds themselves) and method-of-treatment claims (using those compounds to treat NAFLD/NASH/MASH), providing layered exclusivity that is standard practice for pharmaceutical IP as documented by WIPO.
• Granted patent anchor: The grant of US11214563B2 in January 2022 provides a concrete, enforceable IP anchor for the portfolio, with the pending applications building additional protection around it.

“The sustained pace of Terns Pharmaceuticals’ THRβ patent publications — from 2021 through 2024 — indicates active prosecution of a portfolio designed to track and protect a compound moving through clinical development.”

For licensing and business development professionals, the portfolio’s breadth raises important freedom-to-operate questions for any party seeking to develop a selective THRβ agonist for MASH. The combination of multiple chemical scaffold families, composition-of-matter and method-of-treatment claims, and a granted patent anchor creates a comprehensive IP estate that would require careful navigation by any competitor or potential collaborator.

Implications for R&D Strategy and Partnership Decisions

The Terns Pharmaceuticals THRβ patent portfolio has direct implications for R&D strategy across the MASH field. Companies evaluating combination therapy programmes — pairing a THRβ agonist with a GLP-1 receptor agonist, FXR agonist, or another metabolic agent — will need to assess whether TERN-501’s IP position creates licensing opportunities or constraints. Similarly, pharmaceutical companies with established MASH pipelines may view the Terns portfolio as either a competitive threat or an acquisition target, depending on their own strategic positioning. The PatSnap Life Sciences platform provides tools for exactly this kind of competitive IP intelligence, enabling teams to map patent landscapes, identify white spaces, and evaluate licensing opportunities across the MASH therapeutic area. For teams already tracking the broader metabolic liver disease landscape, PatSnap Insights publishes regular analyses of emerging IP trends across drug discovery verticals.